Real-World Results of Low-Dose Tirzepatide for Weight Loss in Italy | Research

The takeaway

Even at the lowest doses (2.5-5 mg), tirzepatide produces meaningful weight loss and metabolic improvements in real-world Italian obesity patients.

Real-world confirmation
Low-dose tirzepatide benefits validated outside clinical trial settings

What the researchers found

Tirzepatide at 2.5 mg and 5.0 mg produced significant short-term weight loss and metabolic improvements in a real-world outpatient obesity population, confirming clinical trial benefits translate to routine practice.

Why it matters

Many patients remain on lower tirzepatide doses for extended periods. Confirming these doses work in real-world settings — not just controlled trials — is essential for clinical confidence.

How the study worked

Retrospective multicenter study across Italian Society of Obesity (SIO) Campania Region clinics evaluating short-term outcomes of tirzepatide 2.5 mg and 5.0 mg in adults with obesity.

What this study cannot tell us

Retrospective design with short follow-up. Single-region study in Italy may not generalize to other populations. No control group for comparison.

How to read the evidence

Retrospective real-world study without a control group — provides practical data but lower evidence grade than RCTs.

When this study was published

Published in 2026; among the first real-world tirzepatide studies from Europe.

The bigger picture

Real-world evidence increasingly complements clinical trial data, helping clinicians set realistic expectations and supporting broader access to newer obesity medications.

Questions still open

How does real-world weight loss at maximum tirzepatide doses compare to trial results?
Do patients who start at lower doses achieve similar long-term outcomes as those who titrate up quickly?

Common questions

Does tirzepatide work at low doses?

Yes, this real-world study confirms that even the starting doses of 2.5 mg and 5 mg tirzepatide produce meaningful weight loss and metabolic improvements in routine clinical practice.

How does real-world tirzepatide compare to clinical trials?

Early real-world data suggests benefits are consistent with trial results, though individual responses vary. The key finding is that lower doses still provide clinically relevant improvements.

Read the original research

Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity - Campania Region.

EXCLI journal, 25, 191-203

View on PubMed ↗Publisher’s paper ↗

Citation

Barrea, Luigi; Verde, Ludovica; Galasso, Martina; Patrone, Renato; Digitale, Lucia; Limardi, Alessandro; Orio, Marcello; Ragozzino, Giovanni; Digitale, Luigi; Salvatore, Vittorio; Savoia, Antonella; Savastano, Silvia; Colao, Annamaria; Muscogiuri, Giovanna. (2026). Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity - Campania Region.. EXCLI journal, 25, 191-203. https://doi.org/10.17179/excli2025-9067